Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Xenon Pharmaceuticals Inc.

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Reports Q2 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon to Report Q2 2024 Financial Results on August 8, 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Tickers XENE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.